查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1495995

全球皮膚病治療市場：2024-2029 年預測

Global Dermatological Drug Market - Forecasts from 2024 to 2029
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 125 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

預計在預測期內，皮膚科治療市場將以 9.10% 的複合年成長率成長，從 2022 年的 299.31 億美元增至 2029 年的 550.76 億美元。

皮膚科是治療皮膚、頭髮和指甲疾病的醫學領域，其中最常見的是乾癬、濕疹和尋常性痤瘡。皮膚科藥物用於治療和控制皮膚、指甲、頭髮和生殖膜疾病。近年來，由於全球營養缺乏、不良飲食習慣、壓力增加、污染和免疫力減弱，患有皮膚病的人數迅速增加。

因此，對治療皮膚病的適當治療方法和皮膚病藥物的需求正在增加。市場區隔是按適應症、給藥途徑、最終用戶和地區分類的。

市場促進因素

  • 皮膚病患病率的增加和醫療保健領域研發的活性化預計將導致市場快速擴張。

推動皮膚病治療產業的最重要因素之一是皮膚病患病率的上升。創傷、環境因素、遺傳因素和老齡化只是導致全世界數百萬人患有皮膚病的主要變數中的一些。自2013年以來，世界各地都慶祝世界皮膚健康日，以提高人們的認知並治療各種皮膚病。據世界衛生組織 (WHO) 稱，皮膚病是最常見的健康疾病之一，在任何特定時間都會影響全球近 9 億人。

隨著老齡化，人類皮膚開始失去健康功能，導致各種皮膚病的發生，皮膚科藥物市場正在不斷發展。此外，隨著年齡的成長，我們開始遇到各種其他問題，包括傷口癒合緩慢、對紫外線 (UV) 輻射的敏感性增加、對感染疾病的敏感性增加以及皮下脂肪減少。根據澳洲的一項研究，尋常性痤瘡長期影響超過 4% 的人口。因此，由於皮膚病發生頻率的增加和對有效藥物的需求增加，預計市場在預測期內將以更快的速度發展。

據美國皮膚病學會稱，痤瘡是最常見的皮膚病，每年影響美國4000 至 5000 萬人。這種情況在年輕人中更為常見，12 歲至 24 歲之間的人中有 85% 患有某種形式的痤瘡。據美國紅斑痤瘡協會稱，酒糟患者數量正在增加，僅在美國就有 1600 萬人患有這種疾病。全球皮膚科藥品市場可能會受到定期推出新穎且以客戶為中心的產品的進一步影響。例如，Sol-Gel Technologies 於 2021 年 7 月宣布 TWYNEO 獲得 FDA 批准。這是一種外用乳膏，用於治療成人和 9 歲以上兒童的尋常痤瘡。

市場限制：

  • 由於產品使用不當而產生不良反應的風險可能成為皮膚病治療市場的限制因素。

新興國家因不良飲食習慣、污染以及吸煙、飲酒等不健康的生活習慣而遭受皮膚感染疾病的人口占世界人口的很大一部分。在低收入和中等收入國家，由於缺乏有關皮膚問題的資訊和高文盲率，皮膚科治療的普及正在下降。與產品相關的不利影響也是阻礙市場成長的問題。例如，美國食品藥物管理局(FDA) 已發布關於使用某些可能引起危及生命的過敏反應的非處方藥的建議。預計這將減少產品的採用並降低皮膚病治療的市場價值。

預計北美將在全球市場中佔據主要佔有率。

由於皮膚病治療藥物易於取得，預計在預測期內北美將佔據皮膚病治療市場的很大一部分。此外，皮膚炎、痤瘡、乾癬等皮膚病發病率的增加也是推動該市場成長的一個突出因素。同時，人們對皮膚病治療方法的認知不斷提高也推動了該市場的成長。

隨著技術的進步，有關皮膚科藥物使用的常識也有所增加。此外，透過提高人們的美學敏感性，他們正在幫助擴大皮膚科治療的市場。

主要進展

  • 2023 年 12 月 - Arcutis Biotherapeutics 宣布羅氟司特霜 (ZORYVE) 0.3% 外用泡沫，一種外用磷酸二酯酶 4 抑製劑，用於治療 12 歲及以上人群的斑塊狀斑塊型乾癬和9 歲及以上族群的脂漏性皮膚炎獲得FDA核准。 Zorive Foam 是一種每日一次、不含類固醇、安全、有效且耐受性良好的泡沫，可用於所有受影響的區域，包括頭髮。
  • 2023 年 1 月 - 百時美施貴寶 (Bristol-Myers Squibb) 的口服藥物 Sotyktu 用於治療中度至重度斑塊型乾癬成人患者獲得了 CHMP 的積極評價。 Sotyktu 是一種選擇性 TYK2 抑制劑，與安慰劑和 Otezla 相比，在皮膚清除、症狀負擔和生活品質方面表現出顯著改善。歐盟委員會審查的建議該藥物耐受性良好，因不利事件而停藥的比率較低。 FDA 於 2022 年 9 月核准了Sotyktu，在日本，厚生勞動省核准將其用於對傳統治療沒有充分反應的斑塊型乾癬、全身膿皰型乾癬和紅皮病型乾癬成人患者。
  • 2022年1月－美國食品藥物管理局（FDA）核准RINVOQ®（通用名： Upadacitinib ）用於治療成人及12歲以上兒童的中度至重度異位性皮膚炎。此次核准是基於一項涉及 2,500 多名患者的 3 期項目的有效性和安全性資料。在同一項研究中，與安慰劑相比，搔癢早在第 1 週就顯著改善，早在第 16 週就觀察到皮膚清除情況。在美國，RINVOQ 15mg 和 30mg 被核准用於患有難治性中度至重度異位性皮膚炎的成人和兒童患者。

目錄

第1章簡介

  • 市場概況
  • 市場定義
  • 調查範圍
  • 市場區隔
  • 貨幣
  • 先決條件
  • 基準年和預測年時間表
  • 相關利益者的主要利益

第2章調查方法

  • 研究設計
  • 調查過程

第3章執行摘要

  • 主要發現

第4章市場動態

  • 市場促進因素
  • 市場限制因素
  • 波特五力分析
  • 產業價值鏈分析
  • 分析師觀點

第5章全球皮膚病治療市場：依適應症分類

  • 介紹
  • 乾癬
    • 市場機會和趨勢
    • 成長前景
    • 地域獲利能力
  • 粉刺
    • 市場機會和趨勢
    • 成長前景
    • 地域獲利能力
  • 皮膚炎
    • 市場機會和趨勢
    • 成長前景
    • 地域獲利能力
  • 其他
    • 市場機會和趨勢
    • 成長前景
    • 地域獲利能力

第6章皮膚病治療的全球市場：途徑分類

  • 介紹
  • 外用
    • 市場機會和趨勢
    • 成長前景
    • 地域獲利能力
  • 口服
    • 市場機會和趨勢
    • 成長前景
    • 地域獲利能力
  • 胃腸外的
    • 市場機會和趨勢
    • 成長前景
    • 地域獲利能力

第7章全球皮膚病治療市場：依最終用戶分類

  • 介紹
  • 醫院和診所
    • 市場機會和趨勢
    • 成長前景
    • 地域獲利能力
  • 化妝品中心
    • 市場機會和趨勢
    • 成長前景
    • 地域獲利能力
  • 其他
    • 市場機會和趨勢
    • 成長前景
    • 地域獲利能力

第8章全球皮膚科治療市場：按地區

  • 介紹
  • 北美洲
    • 按指示
    • 依給藥途徑
    • 按最終用戶
    • 按國家/地區
  • 南美洲
    • 按指示
    • 依給藥途徑
    • 按最終用戶
    • 按國家/地區
  • 歐洲
    • 按指示
    • 依給藥途徑
    • 按最終用戶
    • 按國家/地區
  • 中東/非洲
    • 按指示
    • 依給藥途徑
    • 按最終用戶
    • 按國家/地區
  • 亞太地區
    • 按指示
    • 依給藥途徑
    • 按最終用戶
    • 按國家/地區

第9章競爭環境及分析

  • 主要企業及策略分析
  • 市場佔有率分析
  • 合併、收購、協議和合作
  • 競爭對手儀表板

第10章 公司簡介

  • AbbVie Inc
  • Amgen Inc
  • GlaxoSmithKline Plc
  • Johnson & Johnson
  • Leo Pharma A/S
  • Merck KGaA
  • Nestle SA
  • Novartis AG
  • Pfizer Inc
  • Curatio Healthcare
簡介目錄
Product Code: KSI061612156

The global dermatological drug market is projected to grow at a CAGR of 9.10% during the forecast period to reach US$55.076 billion by 2029, up from US$29.931 billion in 2022.

Dermatology is a field of medicine that deals with diseases of the skin, hair, and nails, with psoriasis, eczema, and acne vulgaris being the most common. Dermatology medications are used to treat and manage diseases of the skin, nails, hair, and genital membranes. Due to reasons such as nutritional inadequacy, bad eating habits, increased stress, pollution, and a lack of immunity in the worldwide population, the pool of people affected by dermatological problems has rapidly expanded in recent years.

The demand for appropriate treatment methods and dermatological medications for the treatment of dermatological disorders has risen as a result. The global dermatological drug market is segmented by indication, route of administration, end-user, and geography.

Market Drivers:

  • The increasing prevalence of dermatological conditions and the rise in research and development in healthcare are anticipated to surge the market.

One of the most important factors driving the dermatological medication industry is the rising prevalence of skin diseases. Trauma, environmental and hereditary factors, and age are only a few of the major variables that contribute to the development of skin diseases in millions of people around the world. Since 2013, World Skin Health Day has been observed around the world to raise awareness of and treat a variety of skin conditions. According to the World Health Organization (WHO), skin diseases are one of the most common types of health disorders, affecting nearly 900 million people worldwide at any given time.

The healthy functioning of the human skin begins to deteriorate with age, leading to an incidence of various skin diseases, propelling the dermatology drug market forward. Furthermore, as people get older, they begin to experience a variety of other issues, including slower wound healing, increased sensitivity to ultraviolet (UV) radiation, increased susceptibility to infections, and a loss of subcutaneous fat. According to Australian research, acne vulgaris affects more than 4% of the population in the long run. As a result, the market is expected to develop at a faster rate during the projected period due to an increase in the frequency of skin diseases and the demand for effective medications.

Acne is the most common skin disorder, according to the American Academy of Dermatology, impacting 40 to 50 million people in the United States each year. It is more common in younger people, with 85% of people aged 12 to 24 suffering from some kind of acne. According to the National Rosacea Society, the rosacea patient population is rising, with 16 million people in the United States alone suffering from the condition. The worldwide dermatological pharmaceutical market is likely to be impacted further by the regular release of novel and customer-centric products. For example, Sol-Gel Technologies announced FDA clearance of TWYNEO in July 2021. It's a topical cream for the treatment of acne vulgaris in adults and children aged 9 and above.

Market Restraint:

  • Risks of negative effects from incorrect product use can act as a limitation on the market for dermatological drugs.

Emerging countries account for a large share of the global population with dermatological infections owing to poor diet, pollution, and unhealthy habits such as smoking and drinking. Lack of information on skin problems, as well as a higher illiteracy rate, have resulted in decreased adoption of dermatological treatments in low-middle-income nations. The negative effects connected with the products are another issue impeding the market's growth. For example, the US Food and Drug Administration (FDA) has issued an advisory regarding the use of certain over-the-counter drugs that might induce life-threatening allergic reactions. This is anticipated to reduce product adoption, resulting in a drop in the market value of dermatology medications.

North America is expected to hold a significant share of the global market.

Due to the simple availability of dermatological drugs, North America is estimated to account for a large proportion of the dermatological drug market over the forecast period. Furthermore, an increase in the occurrence of skin ailments such as dermatitis, acne, and psoriasis is a prominent factor driving this market's rise. On the other hand, due to increased awareness about the usage of dermatological medications,

As technology advances, there is a rise in public knowledge about the usage of dermatological medications. Furthermore, it helps with the expansion of the dermatological medication market by increasing people's aesthetic sensibility.

Key Developments:

  • December 2023- Arcutis Biotherapeutics received FDA approval for its roflumilast cream (ZORYVE) 0.3% topical foam, a topical phosphodiesterase-4 inhibitor, for plaque psoriasis in patients aged 12 and above and seborrheic dermatitis in individuals aged 9 and older. ZORYVE foam is a safe, effective, and well-tolerated once-daily steroid-free foam for use on all affected areas, including hair-bearing areas. It provides rapid disease clearance and a significant reduction in itch, a common symptom of seborrheic dermatitis.
  • January 2023- Bristol Myers Squibb received a positive CHMP opinion for Sotyktu, an oral medication for adults with moderate-to-severe plaque psoriasis. Sotyktu, a selective TYK2 inhibitor, showed significant improvements in skin clearance, symptom burden, and quality of life compared to placebo and Otezla. The recommendation reviewed by the European Commission. The drug was well tolerated, with a low rate of discontinuation due to adverse events. The FDA approved Sotyktu in September 2022, while Japan's Ministry of Health, Labour and Welfare approved it for adults with plaque psoriasis, generalized pustular psoriasis, and erythrodermic psoriasis who have had inadequate response to conventional therapies.
  • January 2022- The U.S. Food and Drug Administration (FDA) approved RINVOQ(R) (upadacitinib) for treating moderate to severe atopic dermatitis in adults and children aged 12 years and older. The approval is based on efficacy and safety data from a Phase 3 program involving over 2,500 patients. The study showed significant improvement in itch as early as week one and skin clearance at 16 weeks compared to the placebo. In the U.S., RINVOQ 15 mg and 30 mg are approved for use in adults and pediatric patients with refractory, moderate to severe atopic dermatitis.

Key Market Segments:

By Indication

  • Psoriasis
  • Acne
  • Dermatitis
  • Others

By Route Of Administration

  • Topical
  • Oral
  • Parenteral

By End-User

  • Hospitals And Clinics
  • Cosmetic Centers
  • Others

By Geography

  • North America
  • USA
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Spain
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • South Africa
  • Israel
  • Others
  • Asia Pacific
  • China
  • Japan
  • Thailand
  • Indonesia
  • South Korea
  • India
  • Taiwan
  • Others

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. Market Overview
  • 1.2. Market Definition
  • 1.3. Scope of the Study
  • 1.4. Market Segmentation
  • 1.5. Currency
  • 1.6. Assumptions
  • 1.7. Base and Forecast Years Timeline
  • 1.8. Key Benefits to the Stakeholder

2. RESEARCH METHODOLOGY

  • 2.1. Research Design
  • 2.2. Research Processes

3. EXECUTIVE SUMMARY

  • 3.1. Key Findings

4. MARKET DYNAMICS

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. Threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Industry
  • 4.4. Industry Value Chain Analysis
  • 4.5. Analyst View

5. GLOBAL DERMATOLOGICAL DRUG MARKET BY INDICATION

  • 5.1. Introduction
  • 5.2. Psoriasis
    • 5.2.1. Market Opportunities and Trends
    • 5.2.2. Growth Prospects
    • 5.2.3. Geographic Lucrativeness
  • 5.3. Acne
    • 5.3.1. Market Opportunities and Trends
    • 5.3.2. Growth Prospects
    • 5.3.3. Geographic Lucrativeness
  • 5.4. Dermatitis
    • 5.4.1. Market Opportunities and Trends
    • 5.4.2. Growth Prospects
    • 5.4.3. Geographic Lucrativeness
  • 5.5. Others
    • 5.5.1. Market Opportunities and Trends
    • 5.5.2. Growth Prospects
    • 5.5.3. Geographic Lucrativeness

6. GLOBAL DERMATOLOGICAL DRUG MARKET BY ROUTE OF ADMINISTRATION

  • 6.1. Introduction
  • 6.2. Topical
    • 6.2.1. Market Opportunities and Trends
    • 6.2.2. Growth Prospects
    • 6.2.3. Geographic Lucrativeness
  • 6.3. Oral
    • 6.3.1. Market Opportunities and Trends
    • 6.3.2. Growth Prospects
    • 6.3.3. Geographic Lucrativeness
  • 6.4. Parenteral
    • 6.4.1. Market Opportunities and Trends
    • 6.4.2. Growth Prospects
    • 6.4.3. Geographic Lucrativeness

7. GLOBAL DERMATOLOGICAL DRUG MARKET BY END-USER

  • 7.1. Introduction
  • 7.2. Hospitals And Clinics
    • 7.2.1. Market Opportunities and Trends
    • 7.2.2. Growth Prospects
    • 7.2.3. Geographic Lucrativeness
  • 7.3. Cosmetic Centers
    • 7.3.1. Market Opportunities and Trends
    • 7.3.2. Growth Prospects
    • 7.3.3. Geographic Lucrativeness
  • 7.4. Others
    • 7.4.1. Market Opportunities and Trends
    • 7.4.2. Growth Prospects
    • 7.4.3. Geographic Lucrativeness

8. GLOBAL DERMATOLOGICAL DRUG MARKET BY GEOGRAPHY

  • 8.1. Introduction
  • 8.2. North America
    • 8.2.1. By Indication
    • 8.2.2. By Route of Administration
    • 8.2.3. By End-User
    • 8.2.4. By Country
      • 8.2.4.1. USA
        • 8.2.4.1.1. Market Opportunities and Trends
        • 8.2.4.1.2. Growth Prospects
      • 8.2.4.2. Canada
        • 8.2.4.2.1. Market Opportunities and Trends
        • 8.2.4.2.2. Growth Prospects
      • 8.2.4.3. Mexico
        • 8.2.4.3.1. Market Opportunities and Trends
        • 8.2.4.3.2. Growth Prospects
  • 8.3. South America
    • 8.3.1. By Indication
    • 8.3.2. By Route of Administration
    • 8.3.3. By End-User
    • 8.3.4. By Country
      • 8.3.4.1. Brazil
        • 8.3.4.1.1. Market Opportunities and Trends
        • 8.3.4.1.2. Growth Prospects
      • 8.3.4.2. Argentina
        • 8.3.4.2.1. Market Opportunities and Trends
        • 8.3.4.2.2. Growth Prospects
      • 8.3.4.3. Others
        • 8.3.4.3.1. Market Opportunities and Trends
        • 8.3.4.3.2. Growth Prospects
  • 8.4. Europe
    • 8.4.1. By Indication
    • 8.4.2. By Route of Administration
    • 8.4.3. By End-User
    • 8.4.4. By Country
      • 8.4.4.1. Germany
        • 8.4.4.1.1. Market Opportunities and Trends
        • 8.4.4.1.2. Growth Prospects
      • 8.4.4.2. France
        • 8.4.4.2.1. Market Opportunities and Trends
        • 8.4.4.2.2. Growth Prospects
      • 8.4.4.3. United Kingdom
        • 8.4.4.3.1. Market Opportunities and Trends
        • 8.4.4.3.2. Growth Prospects
      • 8.4.4.4. Spain
        • 8.4.4.4.1. Market Opportunities and Trends
        • 8.4.4.4.2. Growth Prospects
      • 8.4.4.5. Others
        • 8.4.4.5.1. Market Opportunities and Trends
        • 8.4.4.5.2. Growth Prospects
  • 8.5. Middle East and Africa
    • 8.5.1. By Indication
    • 8.5.2. By Route of Administration
    • 8.5.3. By End-User
    • 8.5.4. By Country
      • 8.5.4.1. Saudi Arabia
        • 8.5.4.1.1. Market Opportunities and Trends
        • 8.5.4.1.2. Growth Prospects
      • 8.5.4.2. South Africa
        • 8.5.4.2.1. Market Opportunities and Trends
        • 8.5.4.2.2. Growth Prospects
      • 8.5.4.3. Israel
        • 8.5.4.3.1. Market Opportunities and Trends
        • 8.5.4.3.2. Growth Prospects
      • 8.5.4.4. Others
        • 8.5.4.4.1. Market Opportunities and Trends
        • 8.5.4.4.2. Growth Prospects
  • 8.6. Asia Pacific
    • 8.6.1. By Indication
    • 8.6.2. By Route of Administration
    • 8.6.3. By End-User
    • 8.6.4. By Country
      • 8.6.4.1. China
        • 8.6.4.1.1. Market Opportunities and Trends
        • 8.6.4.1.2. Growth Prospects
      • 8.6.4.2. Japan
        • 8.6.4.2.1. Market Opportunities and Trends
        • 8.6.4.2.2. Growth Prospects
      • 8.6.4.3. Thailand
        • 8.6.4.3.1. Market Opportunities and Trends
        • 8.6.4.3.2. Growth Prospects
      • 8.6.4.4. Indonesia
        • 8.6.4.4.1. Market Opportunities and Trends
        • 8.6.4.4.2. Growth Prospects
      • 8.6.4.5. South Korea
        • 8.6.4.5.1. Market Opportunities and Trends
        • 8.6.4.5.2. Growth Prospects
      • 8.6.4.6. India
        • 8.6.4.6.1. Market Opportunities and Trends
        • 8.6.4.6.2. Growth Prospects
      • 8.6.4.7. Taiwan
        • 8.6.4.7.1. Market Opportunities and Trends
        • 8.6.4.7.2. Growth Prospects
      • 8.6.4.8. Others
        • 8.6.4.8.1. Market Opportunities and Trends
        • 8.6.4.8.2. Growth Prospects

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 9.1. Major Players and Strategy Analysis
  • 9.2. Market Share Analysis
  • 9.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 9.4. Competitive Dashboard

10. COMPANY PROFILES

  • 10.1. AbbVie Inc
  • 10.2. Amgen Inc
  • 10.3. GlaxoSmithKline Plc
  • 10.4. Johnson & Johnson
  • 10.5. Leo Pharma A/S
  • 10.6. Merck KGaA
  • 10.7. Nestle S.A
  • 10.8. Novartis AG
  • 10.9. Pfizer Inc
  • 10.10. Curatio Healthcare